+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amyotrophic Lateral Sclerosis Treatment Market by Treatment, Type, Treatment Stage, Route of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Amyotrophic Lateral Sclerosis Treatment Market by Treatment, Type, Treatment Stage, Route of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Amyotrophic Lateral Sclerosis Treatment Market by Treatment, Type, Treatment Stage, Route of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305507
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Amyotrophic Lateral Sclerosis (ALS) Treatment Market is experiencing substantial transformation, driven by advancements in genetic therapies, shifting regulatory priorities, and collaborative innovation among stakeholders. For decision-makers seeking to understand new therapeutic frontiers and commercial shifts, this report delivers actionable intelligence for confident planning and partnership.

Market Snapshot: ALS Treatment Market Size & Growth

The ALS Treatment Market grew from USD 688.06 million in 2024 to USD 733.06 million in 2025. It is projected to continue its upward trajectory at a CAGR of 6.89%, reaching USD 1.02 billion by 2030. These figures reflect robust expansion, with industry players leveraging technological advancements and strategic alliances to redefine clinical outcomes and commercial opportunities in ALS therapeutics.

Scope & Segmentation

This report delivers a structured analysis of the ALS Treatment Market, dissecting the sector across major parameters, ensuring decision-makers can target high-impact segments.

  • Treatment Methods: Medication options covering Dextromethorphan/Quinidine, Edaravone, Riluzole, and Tofersen; therapy options include Gene Therapy and Stem Cell Therapy.
  • ALS Types: Familial ALS and Sporadic ALS, reflecting nuances in genetic drivers and clinical pathways.
  • Treatment Stages: Early Stage, Mid Stage, and Advanced Stage interventions, informing clinical research and payer discussions.
  • Routes of Administration: Intrathecal, Intravenous, and Oral, supporting differentiated treatment strategies and patient adherence considerations.
  • Distribution Channels: Hospital Pharmacies and Retail Pharmacies, influencing patient access and supply chain planning.
  • Regional Coverage: Americas (including key US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (countries spanning Western Europe, Gulf Cooperation Council, Sub-Saharan Africa, Nordics, and Eastern Europe), Asia-Pacific (notable economies such as China, Japan, India, Australia, South Korea, and ASEAN countries).
  • Companies Profiled: Industry leaders and innovators including AB Science SA, Amylyx Pharmaceuticals, Biogen Inc., BrainStorm Cell Limited, Cytokinetics, F. Hoffmann-La Roche Ltd, Ionis Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co., Pfizer Inc., and additional established and emerging organizations.

Key Takeaways for Senior Decision-Makers

  • Collaboration between academia, biotechs, and global pharmaceuticals is accelerating the development of disease-modifying therapies, shifting focus from symptomatic management toward personalized interventions.
  • Segmented approaches—by ALS type, stage, and delivery route—are crucial for aligning R&D expenditures, clinical trial design, and payer engagement with unmet needs.
  • Investment in digital monitoring platforms and real-world evidence is shortening clinical development cycles while supporting robust post-market safety data collection.
  • Regional market differences demand adaptive pricing, regulatory, and launch strategies, given disparities in reimbursement policies and patient access infrastructure.
  • Strategic partnerships, focused on gene and cell therapy expertise, offer competitive advantage by expediting translational science and expanding international reach.
  • Organizations prioritizing supply chain flexibility and risk-sharing commercial models are better positioned to withstand market volatility and regulatory headwinds.

Tariff Impact: Navigating U.S. Policy Shifts

Cumulative tariffs introduced in the United States from 2025 are altering manufacturing and distribution economics for ALS therapies. Drug developers are refining procurement strategies, assessing near-shoring opportunities, and renegotiating contracts to offset these pressures. Payers and health systems are monitoring list price movement and adjusting reimbursement plans accordingly. Both new entrants and incumbents are recalibrating launch timings and commercialization models to sustain broad therapy adoption and limit exposure to tariff-induced cost shocks.

Methodology & Data Sources

A mixed-method approach underpins this report. Primary research involved interviews with clinicians, regulators, and market access experts, as well as payer and advocacy surveys. Secondary validation included peer-reviewed literature, industry databases, and regulatory filings. Data normalization and segmentation analysis enabled accurate interpretation of historical trends and market drivers, supporting actionable recommendations.

Why This Report Matters

  • Enables executives to prioritize pipeline investments and partnership opportunities with insight into emerging therapeutic modalities and high-growth submarkets.
  • Supports risk assessment and supply chain decision-making in response to regulatory, policy, and economic fluctuations specific to ALS treatment.
  • Offers a validated framework for benchmarking competitors, structuring cross-border launches, and maximizing patient access through flexible commercial strategies.

Conclusion

This analysis offers a strategic lens on the ALS Treatment Market’s evolution. Leaders who harness data-driven insight and adapt to emerging dynamics are poised to shape the next phase of innovation in ALS care and patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence and rising incidence of amyotrophic lateral sclerosis
5.1.1.2. Increased focus on gene therapy and regenerative medicine as potential avenues for effective ALS treatment
5.1.1.3. Rising establishment of specialized ALS treatment centers and supportive health infrastructure
5.1.2. Restraints
5.1.2.1. Limited treatment efficacy concern associated with ALS treatments
5.1.3. Opportunities
5.1.3.1. Expansion of clinical trial networks that support faster evaluations and better patient outcomes
5.1.3.2. Supportive public-private source for research initiatives in ALS treatment
5.1.4. Challenges
5.1.4.1. Stringent approval processes for ALS therapeutics
5.2. Market Segmentation Analysis
5.2.1. Treatment: Significant usage of the medication owing to their ability to slow disease progression and extend survival in ALS patients
5.2.2. Type: Ongoing research into identifying reliable biomarkers for sporadic ALS
5.2.3. Treatment Stage: Optimizing quality of life and symptom management in advanced-stage amyotrophic lateral sclerosis treatment
5.2.4. Route of Administration: Rising preference for oral administration for its ease of use and flexibility in dosing schedules
5.2.5. Distribution Channel: Expanding role of retail pharmacies in delivering ALS treatments
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment
6.1. Introduction
6.2. Medication
6.2.1. Dextromethorphan/Quinidine
6.2.2. Edaravone
6.2.3. Riluzole
6.2.4. Tofersen
6.3. Therapies
6.3.1. Gene Therapy
6.3.2. Stem Cell Therapy
7. Amyotrophic Lateral Sclerosis Treatment Market, by Type
7.1. Introduction
7.2. Familial ALS
7.3. Sporadic ALS
8. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage
8.1. Introduction
8.2. Advanced Stage Treatment
8.3. Early Stage Treatment
8.4. Mid Stage Treatment
9. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration
9.1. Introduction
9.2. Intrathecal
9.3. Intravenous
9.4. Oral
10. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
11. Americas Amyotrophic Lateral Sclerosis Treatment Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Scenario Analysis
14.3.1. Revive Therapeutics enhances ALS treatment prospects with DiagnaMed molecular hydrogen IP acquisition LOI
14.3.2. Woolsey secures extended series B funding to advance ALS treatment
14.3.3. LifeArc partnership with Neuropeutics Inc. for advance ALS therapy development
14.3.4. FDA lifts clinical hold on Phase 1 trial of AMX0114’s safety and biomarker evaluation in ALS treatment
14.3.5. Alchemab Therapeutics and Lilly partner to pioneer novel ALS therapies
14.3.6. Dewpoint and Mitsubishi Tanabe forge USD 480M partnership to advance ALS therapy
14.3.7. Eisai launches Rozebalamin for injection 25 mg for ALS treatment in Japan
14.3.8. Verge Genomics collaborates with Lilly to enhance development of novel ALS treatments
14.3.9. Leal Therapeutics secures USD 45 million in funding to advance LTX-002 ALS therapy
14.3.10. NLS Pharmaceutics and Kadimastem enter a strategic merger to accelerate ALS treatment innovation
14.3.11. NeuroSense seeks early commercialization approval for ALS treatment in Canada
14.4. Strategy Analysis & Recommendation
14.4.1. Mitsubishi Tanabe Pharma Corporation
14.4.2. Amylyx Pharmaceuticals Inc.
14.4.3. Ionis Pharmaceuticals, Inc.
14.4.4. Aquestive Therapeutics Inc.
List of Figures
FIGURE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
FIGURE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 19. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 21. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 27. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 57. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 59. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 64. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 93. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 94. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 96. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 100. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 101. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 103. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 114. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 115. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 117. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 155. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 156. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 157. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 159. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 176. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 178. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 179. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 181. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 185. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 186. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 188. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 191. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 192. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 193. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 194. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 195. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 199. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 200. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 201. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 202. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 205. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 206. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 207. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 209. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 220. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 221. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 222. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 223. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 240. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 241. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 242. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 243. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 244. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 247. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 248. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 249. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 250. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 251. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 255. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 256. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 258. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 282. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 283. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 284. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 285. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 286. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Amyotrophic Lateral Sclerosis Treatment market report include:
  • AB Science SA
  • Alector, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aquestive Therapeutics, Inc.
  • Ascend Pharmaceuticals LLC
  • AstraEureka Pharmaceuticals
  • Biogen Inc.
  • BrainStorm Cell Limited
  • Cipla Limited
  • CorestemChemon Inc.
  • Coya Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • Dewpoint Therapeutics, Inc.
  • DR. REDDY’S LABORATORIES LIMITED
  • F. Hoffmann-La Roche Ltd
  • Genervon Biopharmaceuticals, LLC
  • GlaxoSmithKline PLC
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurimmune AG
  • Novartis AG
  • ONO PHARMACEUTICAL CO., LTD.
  • Orion Corporation
  • Orphazyme A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Treeway B.V.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 733.06 Million
Forecasted Market Value ( USD ) by 2030 $ 1020 Million
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned37

Related Topics

Related Reports

Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region 2025-2033 - Product Image

Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region 2025-2033

  • Report
  • 140 Pages
  • Global
From
Amyotrophic Lateral Sclerosis - Global Strategic Business Report - Product Image

Amyotrophic Lateral Sclerosis - Global Strategic Business Report

  • Report
  • 183 Pages
  • Global
From
Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast 2025-2034 - Product Image

Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035 - Product Image

Amyotrophic Lateral Sclerosis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2024 - Product Image

Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 447 Pages
  • Global
From

About the Amyotrophic Lateral Sclerosis Drug Market

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. As a result, patients experience muscle weakness, paralysis, and eventually death. The ALS drug market is a subset of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The ALS drug market is relatively small compared to other CNS drug markets, but it is growing due to increased awareness and research into the disease. The ALS drug market is composed of both generic and branded drugs. Generic drugs are typically used to treat the symptoms of ALS, while branded drugs are used to slow the progression of the disease. Currently, there are several companies that are actively researching and developing new treatments for ALS, including Biogen, Novartis, and Sanofi. Additionally, there are several companies that are focused on providing generic drugs to treat the symptoms of ALS, such as Mylan and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.